News

EMA Suspends Rosiglitazone; Defends Time Taken


 

“By severely restricting access to Avandia, the FDA is ensuring that only a few individuals in America will continue to take this drug. Only those patients who have failed to respond to all other therapies will be eligible to receive Avandia,” said Dr. Nissen, chairman of the department of Cardiovascular Medicine, Cleveland Clinic Foundation.

Pages

Recommended Reading

FDA Reviewing Actos's Safety
MDedge Internal Medicine
Metabolic Syndrome Threatens Heart Health Regardless of Diabetes Status
MDedge Internal Medicine
FDA Panel Votes to Approve Dabigatran for Reduction of Stroke Risk
MDedge Internal Medicine
Self-Management Techniques Fail to Improve Heart Failure
MDedge Internal Medicine
Type 2 Diabetes Screening Beneficial, Regardless of Treatment Intensity
MDedge Internal Medicine
TAVI Termed the First Choice for Patients Who Cannot Have Surgery
MDedge Internal Medicine
Novel Antiplatelet Drug Elinogrel Moves Into Phase III Testing
MDedge Internal Medicine
'Stars' of CABG Featured on Consumer Reports Site
MDedge Internal Medicine
Daily BNP Injections Show Heart Failure Efficacy in Pilot Clinical Study
MDedge Internal Medicine
Reports Shows Progress, Pitfalls in Women's Health Research
MDedge Internal Medicine